Sign in Sign up for free

Acelrx Pharmaceuticals Inc EPS Q/Q

What is the EPS Q/Q of Acelrx Pharmaceuticals Inc?

The EPS Q/Q of Acelrx Pharmaceuticals Inc is -12,100.00%

What is the definition of EPS Q/Q?



Quarterly EPS growth rate, year over year, is the increase of the company’s EPS for the most recent quarter compared to the the same quarter in the previous year.

quarterly growth yoy (year over year)

The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

EPS Q/Q of companies in the Health Care sector on NASDAQ compared to Acelrx Pharmaceuticals Inc

What does Acelrx Pharmaceuticals Inc do?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Companies with eps q/q similar to Acelrx Pharmaceuticals Inc